REFERENCES
- WHO TFI http://www.who.int/tobacco/about/en/index.html (accessed 22 April 2011)
- WHO FCTC http://www.who.int/fctc/about/en/ (accessed 22 April 2011)
- Tonstad S. Tonnesen P. Hajek P. Williams, K E, Billing C B, Reeves K R. Effect of maintenance therapy with varenicline on smoking cessation. JAMA 2006; 296(1): 64–71.
- Knight C, Howard P. Baker C, Marton J. The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model. Value Health 2010; 13(2): 209–214.
- Annemans L, Nackaerts K, Bartsch P. Prignot J, Marbaix S. Cost-effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement ther-apy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis. Clin Drug Investig 2009; 29(10): 655–665.
- Howard P. Knight C, Boler A, Baker C. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model. Pharmacoeconomics 2008; 26: 497–511.
- Federal Public Service For Economy. Available from URL: http://statbel.fgov.be/fr/modules/publications/statistiques/population/downloads/population_par_sexe_groupe_et_classe_d_ges_la_belgique_et_par_region.jsp. Accessed on July 2011.
- PBAC guidelines. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) (Version 4.3). Appendix 6: Utility valuation of health outcomes. Available from URL: http://www.pbs.gov.au/info/industry/listing/elements/pbac-guidelines/e-appendixes/f-appendix-6. Accessed on December 2011.
- Institut scientifique Santé Publique. Health interview survey 2008, Interactive analyses [online]; Available from URL: http://www.iph.fgov.be/EPIDEMIO/hisia/index.htm
- De Granda-Orive JI. Distribution of stages of change in smoking behavior in a group of young smokers (transtheoretical model). Military Medicine 2004; 169(12): 972–975.
- Etter JF, Perneger TV. Associations between the stages of change and the pros and cons of smoking in a longitudinal study of Swiss smokers. Addict Behav 1999; 24(3): 419–424.
- Kviz FJ, Clark MA, Hope H, Davis AM. Patients perceptions of their physician's role in smoking cessation by age and readiness to stop smoking. Prey Med 1997; 26(3): 340–349.
- Martin RA, Velicer WF, Fava JL. Latent transition analysis to the stages of change for smoking cessation. Addict Behav 1996; 21(1): 67–80.
- Velicer WF, Fava JL, Prochaska JO, Abrams DB, Emmons KM, Pierce JP. Distribution of smokers by stage in three representative samples. Prey Med 1995; 24(4): 401–411.
- West R. Getting serious about stopping smoking. A review of products, services and techniques. London: No Smoking Day, 1997.
- Feenstra T, Hamberg-van Reenen H, Hoogenveen R, Rutten-van Molken M. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic mod-eling study. Value Health 2005; 8(3): 178–190.
- Data on file, IMS, Belgium, 2007 Apr.
- Federal Public Service for Economy. Available from URL http://statbel.fgov.be/fr/statistiques/chiffres/population/deces_mort_esp_vie/Mortalite_generale/, Accessed on July 2007.
- Cleemput I, Van wilder P. Vrijens F, Huybrechts M, Ramaekers D. Richtlijnen voor farmaco-economisch onderzoek in Belgie. Brussel: KCE Reports 2008: 78B.
- Jansen J, Fluerence R, Devine B, Itzler R, Barrett A, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Available from URL: http://www.ispor.org/workpa-per/interpreting-indirect-treatment-comparison-and-network-meta-analysis-studies-for-decision-making.pdf. Accessed on December 2011.
- Federal Public Service for Economy. Prix ala consommation. Available from URL: http://statbel.fgov.be/fr/modules/publications/statistiques/economie/prix_a_la_consommation_a_partir_de_1920_et_indice_sante_a_partir_de_1994.jsp. Accessed on July 2011.
- Technische Cel - Cellule Technique (TCT) Banque Nationale de Donnees. Diagonostic medical/soins & cout. Available from URL: https://tct.fgov.be/webetct/etct-web/html/fr/index.jsp, Accessed on July 2011.
- Muls E, van Ganse E, Closon M. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model, Atherosclerosis 137 Suppl. (1998) S111–5116.
- Hajek P. Tonnesen P. Arteaga C, Russ C, Tonstad S. Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatment. Addiction 2009; 104: 1597–1602.
- Bolin K, Wilson K, Benhaddi H, de Nigris E, Marbaix S, Mork A, Aubin H. Cost-effectiveness of varenicline compared with nicotine patches for smoking cessa-tion results from four European countries. EurJ Public Health 2009; 19(6): 650–654.
- Walczak J, Nogas G, Dybek-Karpuik A, Augustynska J, Stelmachowski J, Garbacka M, et al. The cost-effectiveness analysis of varenicline for smoking cessation in Poland. 12th Annual European Congress of the International Soci-ety for Pharmacoeconomics and Outcomes Research. Paris, France, 2009.
- Vemer P. Rutten-van Molken M. Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries. Value Health 2010; 13(2): 230–241.
- Rigotti N, Pipe A, Benowitz N, Arteaga C, Garza D, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease. A ran-domized trial. Circulation 2010; 121: 221–229.
- http://www.fagg-afmps.be/fr/news/news_varenicline.jsp?referer=tcm:291-134941-64 Accessed August 2011Technische Cel - Cellule Technique (TCT) Montants totaux par MDC. Available from URL: https://tct.fgov.be/webetct/etct-web/anonymous?lang=fr
- Boudrez H, Gratziou C, Messig M, Metcalfe M. Effectiveness of varenicline as an aid to smoking cessation: results of an inter-European observational study. Curr Med Res Opin 2011; 27(4): 769–775.
- Hoengenaert J, Boudrez H, Meysman M, Nackaerts K, Wouters M and De Beleyr. Survey on the clinical impact of a 4-hours educational smoking cessation pro-gram in Flemish primary care physicians, abstract presented at SRNT-Europe, Antalya, Sept 2011.
- Annemans L, Lamotte M, Levy E, Lenne X. Cost-effectiveness analysis of clopi-dogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial, J Med Econ 2003; 6: 55–68.